Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study

Nicholas D Giardino1,3*, Jeffrey L Curtis2,4, Adin-Cristian Andrei2, Vincent S Fan5, Joshua O Benditt3, Mark Lyubkin1,3, Keith Naunheim6, Gerard Criner7, Barry Make8, Robert A Wise9, Susan K Murray2, Alfred P Fishman10, Frank C Sciurba11, Israel Liberzon1,3, Fernando J Martinez2, the NETT Research Group

Abstract

Background: Anxiety in patients with chronic obstructive pulmonary disease (COPD) is associated with self-reported disability. The purpose of this study is to determine whether there is an association between anxiety and functional measures, quality of life and dyspnea.

Methods: Data from 1828 patients with moderate to severe emphysema enrolled in the National Emphysema Treatment Trial (NETT), collected prior to rehabilitation and randomization, were used in linear regression models to test the association between anxiety symptoms, measured by the Spielberger State Trait Anxiety Inventory (STAI) and: (a) six-minute walk distance test (6 MWD), (b) cycle ergometry peak workload, (c) St. Georges Respiratory Questionnaire (SGRQ), and (d) UCSD Shortness of Breath Questionnaire (SOBQ), after controlling for potential confounders including age, gender, FEV1 (% predicted), DLCO (% predicted), and the Beck Depression Inventory (BDI).

Results: Anxiety was significantly associated with worse functional capacity [6 MWD (B = -0.944, p < .001), ergometry peak workload (B = -0.087, p = .04)], quality of life (B = .172, p < .001) and shortness of breath (B = .180, p < .001). Regression coefficients show that a 10 point increase in anxiety score is associated with a mean decrease in 6 MWD of 9 meters, a 1 Watt decrease in peak exercise workload, and an increase of almost 2 points on both the SGRQ and SOBQ.

Conclusion: In clinically stable patients with moderate to severe emphysema, anxiety is associated with worse exercise performance, quality of life and shortness of breath, after accounting for the influence of demographic and physiologic factors known to affect these outcomes.

Trail Registration: ClinicalTrials.gov NCT00000606

Background

Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and death. Disability, functional limitations and decreased quality of life in patients with COPD are correlated with objective physiologic measures of disease severity [1-3]. However, a large proportion of the variance in functional status and quality of life associated with COPD is not explained by measures of pulmonary physiology. Psychological factors may play an important role in determining the impact of COPD on patient functioning. For example, anxiety in patients with COPD has been associated with decreased quality of life, more severe dyspnea, greater disability, and impaired functional status [4,5] even after controlling for lung function and the presence of other chronic diseases [6,7]. Anxiety is also a significant predictor of the frequency of hospitalizations for acute exacerbations of COPD [8].

Anxiety is a major clinical problem in patients with COPD. The prevalence of clinical anxiety disorders in patients with COPD is substantially higher than in the...
general public. Anxiety symptoms are very common in patients with COPD. In previously published studies 10-80% of patients endorsed anxiety symptoms [1,7,9-12], exceeding that for patients with other chronic medical conditions such as heart disease, renal disease, AIDS and cancer [13,14]. Estimates for specific anxiety disorders range from a 10-32%, a 3- to 10-fold increase in COPD compared to the general population. The most common anxiety disorders diagnosed with COPD are generalized anxiety disorder and panic disorder, which may occur in as many as one-third of COPD patients [15-17]. Defining the contribution of anxiety to functional impairment in COPD is a first step in determining the potential for interventions to combat anxiety to improve functional status.

Most previous studies of the impact of anxiety on patients with COPD have relied on patient self-report measures of functioning [4,6,7]. In these studies self-report biases may confound the true association between psychological and physical health [18]. Investigations that have included objective measures of functioning (e.g., 6-minute walk distance test (6 MWD)) have been limited by small sample size, or have included only patients selected for high levels of anxiety and depression [5,9].

In the current study, we hypothesized that anxiety would be associated with worse functional performance (6 MWD; maximal exercise capacity), health-related quality of life (SGRQ), and dyspnea (SOBQ), after controlling for the effects of potential confounders including age, pulmonary function and depression. We used data from a carefully characterized large group of patients with severe emphysema who were evaluated for the National Emphysema Treatment Trial (NETT). We also examined whether sex differences existed in the relationship between anxiety symptoms and outcomes variables (6 MWD, maximal exercise capacity, SGRQ, SOBQ).

Methods

Study group

Ethics committee approval for the NETT was obtained from the Institutional Review Boards of all participating sites. Procedures for recruitment, screening, determination of eligibility, and assessments for the NETT are described in detail elsewhere [19,20]. Briefly, 3777 patients were screened for the NETT from 1998 to 2002. Patients were included if they had moderate to severe emphysema, had been nonsmokers for at least 6 months, and did not have clinically significant comorbid conditions or circumstances that placed them at high risk for perioperative morbidity or mortality or made it unlikely that they would complete the trial. In order to maximize generalizability and sample heterogeneity, patients were included in the analyses if they had all of the required data from the initial screening assessment, prior to the start of the pre-randomization rehabilitation program. 1828 patients met these criteria. A total of 1218 patients went on to randomization to receive either lung volume reduction surgery or continued regular medical treatment. Patients failed to reach randomization for a number of reasons, for example failure to complete rehabilitation program and all postrehabilitation and randomization assessments, failure to obtain final approval for surgery just prior to randomization, and other new onset complications that met study exclusion criteria. Although no differences between randomized and non-randomized patients were expected in our analyses, in order to allow comparison with a number of other reports that are based on data only from randomized NETT subjects, our data analyses were also repeated for randomized patients with complete data from the initial screening assessment on all variables analyzed (n = 1154).

Demographic and questionnaire measures

Demographics and self-report measures were collected using standardized instruments including: Spielberger State Trait Anxiety Inventory (STAI) [21]

The STAI is a 40-item self-report measure of enduring (trait) and transient (state) anxiety symptoms. Respondents rate how statements reflect how they generally feel on a 4-point scale. STAI state and trait scores range from 20-80. State anxiety is defined as unpleasant emotional arousal, characterized by feelings of tension and apprehension, and heightened autonomic nervous system activity, while trait anxiety measures a stable tendency to respond with state anxiety. The state anxiety scale of the questionnaire was chosen for our analyses in order to more closely match the time frame referenced by most of our other questionnaire measures (i.e., current, versus past or typical functioning). In addition the state anxiety measurement has been shown to be more valid than that of trait anxiety [22].

Beck Depression Inventory (BDI) [23]

The BDI is a 21 item self-report measure of symptoms of depression. Respondents choose statements that reflect how they have felt over the past 2 weeks. The BDI contains 13 items assessing cognitive-mood depressive symptoms (e.g., sadness, guilt) and 8 items that assess physical-performance symptoms of depression (e.g., fatigue, weight loss, physical health worries).

St. Georges Respiratory Questionnaire (SGRQ) [24]

The SGRQ is a 60-item-disease specific instrument developed for use with patients with airflow limitation and designed to measure health-related quality of life. We used the full-scale SGRQ score in our analysis.

UCSD Shortness of Breath Questionnaire (UCSD-SOBQ) [25]

The UCSD-SOBQ is a 33-item measure of shortness of breath while performing activities.
Questionnaires were administered to subjects after performance of diagnostic testing and determination of study eligibility.

**Physiologic measures**

Pulmonary function tests, including spirometry and single-breath diffusing capacity (DLCO), were performed in accordance with American Thoracic Society standards [26,27]. Spirometry values used in this report (FEV₁) were obtained following bronchodilator (albuterol) administration. Percent of predicted values were calculated using normal reference values derived from Crapo and colleagues [28,29]. The standardized 6 MWD protocol has been described in detail elsewhere [30] and provided maximum distance walked. Maximum exercise capacity (watts) was measured on an electromagnetically-braked cycle ergometer that increased at a rate of 5 or 10 W per minute after 3 minutes of unloaded pedaling while subjects breathed 30 percent oxygen.

**Statistical analysis**

Descriptive statistics were performed. Analysis of variance was used to compare patients who were versus were not randomized in the NETT. For categorical variables a Pearson Chi-square test was performed. Next, four separate multiple linear regression models were computed to test the association between state anxiety and: (a) 6 MWD; (b) maximum exercise capacity; (c) St. Georges Respiratory Questionnaire total score; and (d) UCSD Shortness of Breath Questionnaire total score. In the first regression model, 6 MWD was entered as the dependent variable. Patient age, gender, FEV₁%, DLCO%, Beck Depression Inventory score and Spielberger State Anxiety score were entered as the independent variables. The second through fourth models were identical to the first, except substituting maximum workload on cardiopulmonary exercise test, SGRQ total score, and UCSD SOBQ total score, respectively, as the dependent variable. In order to test for possible collinearity between independent variables, eigenvalues of the scaled and uncentered cross-products matrix, condition indices, variance-decomposition proportions, variance inflation factors (VIF) and tolerances were computed for individual variables. All statistical analyses were performed using SPSS statistical software (SPSS, Inc. Chicago, IL, USA). A probability value of p = .05 was used to determine statistical significance.

The STAI and BDI are not clinical diagnostic tools. However there are published cutoff scores for both instruments to indicate clinically significant symptom levels. In general population samples, cutoff scores of 19 and 40 are used for the STAI [21] and BDI [23], respectively, to indicate clinically significant symptoms and likely diagnosis. For the BDI, scores of 10 or above indicate mild-moderate depressive symptoms. In geriatric outpatient populations higher cutoff scores have been recommended: 22 for the STAI and 44 for the BDI, based on assessment studies in persons aged 55 and older [31,32]. Questions have also been raised about the interpretation of specific depression symptoms in patients with chronic medical illness, including COPD [33,34]. Because of a concern that the full BDI score might overestimate depression severity in patients with more severe emphysema due to overlap between COPD severity and somatically-focused depression symptoms on the BDI (e.g., fatigue, weight loss, physical health worries), we repeated each multiple regression analysis entering the totals of ‘cognitive-mood’ and ‘physical-performance’ BDI items separately as independent variables.

**Results**

In general, this study population was elderly and primarily white; approximately two-thirds were male. Subjects’ age range was 28-89 years, with 96% of patients aged 55 or older. Subjects had severe airflow limitation and impaired diffusing capacity. Compared to published population norms for the SGRQ (mean = 12.17) [35] and 6 MWD (mean = 555 meters) [36] in similar age groups (ages 60-69), subjects in this study showed lower exercise performance and poorer health-related quality of life (Table 1).

Subjects showed moderately high levels of baseline anxiety and depression. Thirty percent of subjects had state anxiety scores above 40 and twenty percent scored above 44. Forty-one percent of subjects had a BDI score of 10 or higher, indicating mild-moderate depressive symptoms. Eight percent of subjects scored 19 or higher on the BDI and 4% scored 22 or higher, indicating moderate-severe symptoms. Women had significantly higher anxiety (36.4 vs. 34.0, p < .001) and depression (10.3 vs. 9.0, p < .001) scores than men. Non-randomized subjects differed significantly from randomized subjects in 6 MWD (337.3 m. vs. 348.0 m., p = .04) and shortness of breath scores (63.5 vs. 65.5, p = .04), with non-randomized subjects showing greater impairment on both variables.

Results of multiple linear regression analyses showed that anxiety was significantly associated with decreased 6 MWD, even after adjusting for patient age, gender, FEV₁ (% predicted), DLCO %, and depression (Table 2). Likewise, anxiety was significantly and inversely associated with maximal workload during cardiopulmonary exercise testing after adjusting for age, gender, FEV₁ %, DLCO %, and depression. Finally, after controlling for patient age, gender, FEV₁ %, DLCO %, and depression score, anxiety was also significantly associated with SGRQ and UCSD Shortness of Breath Questionnaire total scores. Regression coefficients from
models with the BDI mood and physical symptom scores show that a 10-point increase in anxiety score is associated with a mean decrease in 6 MWD of 9 meters, a decrease in maximum exercise workload of almost 1 Watt, and an increase of approximately 2 points on the SGRQ and the UCSD SOBQ. Collinearity diagnostic test did not indicate significant collinearity between independent variables in the regression models (data not shown). Effects for anxiety were similar when limiting analyses to only randomized patients, but were not statistically significant for maximum workload (data not shown).

Total BDI depression score was also significantly associated with 6 MWD (B = -1.12, SE = 0.43, p = .009), peak workload (B = -0.24, SE = .08, p = .002), SGRQ (B = .80, SE = 0.05, p < .001) and UCSD Shortness of Breath Questionnaire (B = 0.950, SE = 0.08, p < .001) total scores. But, when BDI scores were separated into ‘mood’ and ‘physical’ symptoms scores, physical, but not mood, symptoms were associated with the dependent variables in all cases (Table 2).

In separate multivariate regression models predicting 6 MWD, maximum exercise workload, SGRQ, and UCSD Shortness of Breath Questionnaire total scores, a significant interaction was found between gender and anxiety score in predicting SGRQ total score after adjusting for age, FEV1%, DLCO%, and depression score. Anxiety was much more strongly associated with SGRQ for men (B ± SE = 0.23 ± .04; p < .001; 95% confidence interval [0.16, 0.30]), than for women (B ± SE = 0.09 ± .04; p = .03; 95% confidence interval [0.01, 0.18].

**Discussion**

This analysis of a large, prospectively studied cohort of patients with severe emphysema screened for enrollment in a clinical trial of lung volume reduction surgery makes several important observations about state anxiety. We show that state anxiety was significantly and independently associated with 1) shorter 6 MWD distance; 2) diminished maximum workload on cardiopulmonary exercise testing; 3) poorer health-related quality of life, and 4) more shortness of breath. It should be

### Table 1 Characteristics of enrolled NETT patients used in this report* (n = 1828).

| Characteristic                                      | Mean ± SD       |
|----------------------------------------------------|-----------------|
| Age at evaluation (years)                          | 66.7 ± 6.3      |
| Gender                                             | Male 1134 (62%) |
|                                                    | Female 694 (38%) |
| Race/ethnic group                                  | Non-Hispanic white 1727 (94%) |
|                                                    | Non-Hispanic black 73 (4%) |
|                                                    | Other 28 (2%) |
| FEV1 % of predicted                                | 27.1 ± 7.5      |
|                                                    | 0.78 ± 0.25     |
| DLCO % of predicted                                | 28.2 ± 10.1     |
|                                                    | 8.0 ± 3.2       |
| Beck Depression Inventory                          | 9.5 ± 6.0       |
| Spielberger Anxiety Inventory - State              | 34.9 ± 10.9     |
| 6-Minute Walk Test (meters)                        | 344.2 ± 105.8   |
| Maximum Exercise Capacity (watts)                  | 35.6 ± 21.9     |
| St. George’s Respiratory Questionnaire - total score| 564 ± 13.1      |
| UCSD Shortness of Breath Questionnaire (Mean ± SD)  | 64.9 ± 19.4     |

* Includes some patients who were not ultimately randomized to treatment. See Methods for additional details.
emphasized that our measure of anxiety evaluates a general state of feeling anxious and does not indicate how anxious patients actually felt during exercise testing. Emotional distress experienced during exercise may be even more strongly associated with performance outcomes [37-39]. Nonetheless, our findings suggest that anxiety may be a valid target for therapeutic interventions in patients with severe emphysema.

A key feature of our report is the objective measurement of physical functioning using well-validated physiologic measures, which allows us to extend the findings of other investigators who suggested greater impairment in physical functioning and quality of life with increasing levels of anxiety in COPD patients [7,40-42]. Our results contrast with those of Borak et al., who reported no significant effect of anxiety on exercise

| Table 2 Results of multiple linear regression analyses for 6 MWD, maximum exercise, quality of life, and shortness of breath. |
|---------------------------------------------------------------|
| **B** | **SE** | **Beta** | **p** | **95% Confidence Interval for B** | **Model fit** |
| 6MWD | | | | | |
| Age (years) | -2.37 | .37 | -.14 | <.001 | [-3.09, -1.65] | 22 | <.001 |
| Male Gender | 45.04 | 4.78 | .21 | <.001 | [35.67, 54.40] |
| FEV1% | 3.39 | .33 | .25 | <.001 | [2.75, 4.03] |
| DLCO% | 2.61 | .23 | .25 | <.001 | [2.15, 3.06] |
| Depression-M | .26 | .79 | .01 | .746 | [-1.30, 1.81] |
| Depression-P | -2.64 | .85 | -.08 | .002 | [-4.31, -.97] |
| Anxiety | -.99 | .24 | -.10 | <.001 | [-1.45, -.52] |
| Max. exercise | | | | | |
| Age (years) | -62 | .07 | -.18 | <.001 | [-.75, -.49] |
| Male Gender | 20.44 | 85 | .45 | <.001 | [18.77, 22.11] |
| FEV1% | 1.14 | .06 | .40 | <.001 | [1.03, 1.26] |
| DLCO% | .50 | .04 | .23 | <.001 | [42, 58] |
| Depression-M | .21 | .14 | .03 | .142 | [-.07, .49] |
| Depression-P | -.73 | .15 | -.11 | <.001 | [-1.02, -.43] |
| Anxiety | -.10 | .04 | -.05 | .17 | [-.19, -.02] |
| Quality of life | | | | | |
| Age (years) | -26 | .04 | -.13 | <.001 | [-.35, -.18] |
| Male Gender | 1.18 | .56 | .04 | .037 | [.07, 2.29] |
| FEV1% | -.10 | .04 | -.06 | .012 | [-.17, -.02] |
| DLCO% | -.07 | .03 | -.05 | .018 | [-.12, -.01] |
| Depression-M | .31 | .09 | .09 | .001 | [.12, .49] |
| Depression-P | 1.34 | .10 | .33 | <.001 | [1.15, 1.54] |
| Anxiety | -.187 | .03 | -.16 | <.001 | [.13, .24] |
| Shortness of Breath | | | | | |
| Age (years) | -.132 | .07 | -.04 | .045 | [-.26, -.01] |
| Male Gender | -2.940 | 85 | -.07 | .001 | [-.461, -1.27] |
| FEV1% | -.345 | .06 | -.14 | <.001 | [-.46, -.23] |
| DLCO% | -.285 | .04 | -.15 | <.001 | [-.37, -.20] |
| Depression-M | 139 | .14 | .03 | .331 | [-.14, .42] |
| Depression-P | 1.836 | .15 | .30 | <.001 | [1.54, 2.13] |
| Anxiety | 206 | .04 | .12 | <.001 | [12, .29] |

Unstandardized regression coefficients (B), standard errors (SE), standardized coefficients (Beta), significance values (p), and 95% confidence intervals are shown for each independent variable. Goodness-of-fit (R2) shown for each regression model. For each regression model, BDI depression was entered either as total score or as two separate independent variables composed of the mood (Depression-M) or physical (Depression-P) BDI symptom items.

FEV1%: forced expiratory volume in 1 second, percent of predicted.
DLCO%: single-breath diffusing capacity of carbon monoxide, percent of predicted.

http://respiratory-research.com/content/11/1/29
performance [9], however the differences may relate mostly to methodological and data analytical issues. That study examined the effects of a number of psychological variables, including anxiety and depression, on 6 MWD in a group of 49 patients with moderate to severe COPD, and concluded that they had no effect at all on exercise performance. In their analyses, authors entered up to 15 independent variables into a multiple regression equation, with 6 MWD as the dependent variable. With only 49 patients, this model may have been underpowered to detect anything but very large effects. In addition, the power to detect an effect of anxiety was decreased further by the conversion of anxiety to a categorical variable of low, moderate or high based on subjects’ scores on a continuous measure of anxiety. In contrast, our study analyzed anxiety as a continuous variable and, to our knowledge, utilized the largest sample size to date to examine the question.

Our results also contrast with those of Weaver and colleagues [43], who tested a causal model of factors affecting self-reported physical, mental, and social functioning including age, length of illness, FEV1, dyspnea, depression, anxiety, self-esteem, and exercise capacity, as measured by the 12-minute walk test in patients with COPD. They found that anxiety was linked to exercise capacity, but only through its association with depression and dyspnea. It is possible that the differences in findings between these studies are due to the use of different measures of anxiety, depression, and dyspnea. In addition, our subjects were a more homogenous group with more severe COPD and an emphysematous phenotype.

Our analyses showed that depression, as measured by the BDI total score, was significantly associated with poorer exercise performance and worse health-related quality of life scores. But, our results indicate that the observed association between depression and other patient variables was due to the somatic symptoms of depression included on the BDI. These include, for patient variables was due to the somatic symptoms of observed association between depression and other quality of life scores. But, our results indicate that the severe COPD and an emphysematous phenotype.

Several mechanisms, not mutually exclusive, may explain the link between anxiety and functional impairment in patients with COPD. First, anxiety may increase disability in COPD by increasing vigilance for, and amplification of, distressing respiratory sensations. The tendency to misinterpret ambiguous or potentially threatening stimuli, a characteristic of many anxiety disorders, would lead anxious COPD patients to avoid any activity that might produce these sensations. Second, patients with higher anxiety may be more emotionally sensitive to unpleasant somatic sensations, which would lead to greater distress when these bodily cues are encountered. In a recent population-based longitudinal study, anxiety and depression were associated with the new onset of dyspnea, but not vice versa [50]. Third, longitudinal experience with COPD symptoms may generate fearful or catastrophic beliefs about respiratory sensations, which, in turn, provoke anxiety that limits engagement in physical activity. Patients with COPD and panic disorder report more fearful thoughts about, and avoidance of, unpleasant somatic sensations than COPD patients without anxiety [51]. Patients who endorse beliefs such as “dyspnea is always a sign of danger”, or “activities that produce dyspnea make my COPD worse and should be avoided” are more functionally impaired and report poorer quality of life independent of COPD severity [52]. Near-death episodes, need for ventilatory support, and other illness experiences could also influence the development of these fearful beliefs and frightening thoughts.

Why anxiety is so much more common in COPD than in the general population or in other disease states remains unclear. Repetitive experiences with hypoxia and hypercapnia might sensitize neural circuits that
control fear responses, such as neurons in the amygdala and locus ceruleus, to overreact to either subsequent episodes of hypoxia and hypercapnia or to fearful perceptions of conditioned stimuli such as the sensation of breathlessness [53]. These reactions would again lead to avoidance of physical activity and limit exercise performance. In addition, a vicious circle may ensue, in which dyspnea leads to anxiety, which produces a rapid, shallow breathing pattern, leading to air trapping and hyperinflation, creating further dyspnea and exercise limitations [54]. Thus, anxiety in the context of COPD may represent a ‘normal’ response to the anxiogenic experience of repeated dyspnea, hypoxia, or hypercapnia; or it may reflect the presence of a pre-morbid anxiety problem that may become exacerbated in the presence of COPD symptoms. Deciphering the relative contributions of these two pathways to anxiety will require longitudinal studies beginning in more mild stages of COPD.

Our findings suggest that screening for anxiety may be important in patients with moderate to severe COPD. Treating anxiety when present in patients with COPD may not only reduce emotional distress, but also improve physical functioning and overall quality of life. Brief screening instruments have been validated for the detection of anxiety in medical settings [55]. And, while there are no published large randomized controlled studies of treatments for anxiety disorders in patients with COPD, number of studies report decreased anxiety symptoms in COPD with antidepressant therapy [56-59], cognitive-behavioral therapy [60,61], or exercise therapy, including pulmonary rehabilitation [11,62-66].

Our findings from our analysis of data from the NETT have some limitations. As with all research reports from treatment trials such as the NETT, the most serious limitation is related to subject characteristics influenced by study selection criteria and subject self-selection. Subjects in this study had moderate to severe emphysema. In addition, subjects who participated in the NETT were not current cigarette smokers and had agreed to participate in a rigorous pulmonary rehabilitation program. As a result, it is important to note that our findings may not be generalizable to all patients with COPD. Likewise, since only patients with COPD were included (i.e., there was not a non-COPD control group), our results are not generalizable to other patient groups. Second, questionnaires were administered prior to pulmonary rehabilitation and treatment randomization. Thus, while the measures were thus not influenced by the impact of rehabilitation or treatment, it is possible that subjects may have experienced heightened anxiety or mood symptoms in anticipation of rehabilitation participation or treatment assignment.

While the associations between state anxiety and exercise performance found in our study were statistically significant, the absolute effect sizes for anxiety were modest. We found that a 10-point increase in state anxiety score is associated with a mean decrease in 6 MWD of 9 meters, a decrease in maximum exercise workload of approximately 1 Watt, and an increase of approximately 2 points on the SGRQ and the UCSD SOBQ. Published guidelines for the 6 MWD suggest 50 meters change to indicate clinically significant changes in walking distance [67]. For the SGRQ a change in 4 points is used to indicate clinically important differences in health-related quality of life [24]. However these guidelines were based on within-subject changes observed in clinical trials, rather than between-subject differences in cross-sectional studies. Nonetheless, using these figures as a rough guide, a patient with a high state anxiety score (2 SD above the mean or STAI = 57) in our sample would be expected to walk about 40 meters less on the 6 MWD and score 9 points worse on the SGRQ than a patient with low state anxiety (2 SD below the mean, or STAI score = 13). Thus, while the effect of anxiety on patients with COPD appears to be clinically meaningful, the significance of our findings needs to be further evaluated.

Conclusion
In summary, we found that state anxiety is associated with worse functioning on measures of exercise performance, health-related quality of life and shortness of breath in patients with moderate to severe emphysema, after accounting for the influence of demographic and physiologic factors known to affect these outcomes. Our results support the need for additional research into the role of anxiety as an important source of functional impairment and decreased quality of life in patients with COPD. Future studies will need to examine the mechanisms by which anxiety impacts exercise performance.

Acknowledgements
Funding: The National Emphysema Treatment Trial (NETT) is supported by contracts with the National Heart, Lung, and Blood Institute (N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, and N01HR76119); the Centers for Medicare and Medicaid Services (CMS); and the Agency for Healthcare Research and Quality (AHRQ). Dr. Martinez is also supported by 2 K24 HL04212. Dr. Giardino is supported by funding from a Career Development Award from the Clinical Science Research & Development Service, Department of Veterans Affairs. Dr. Curtis is supported by funding from a Research Enhancement Award Program (REAP) from the Biomedical Laboratory Research & Development Service, Department of Veterans Affairs.* Members of the NETT Research Group:
Office of the Chair of the Steering Committee, University of Pennsylvania, Philadelphia, PA: Alfred P. Fishman, MD (Chair), Betsy Ann Bozzarelli, Ameena Al-Amin.
Clinical centers

Bay College of Medicine. Houston, TX: Marca Katz, MD (Principal Investigator); Carolyn Wheeler, RN, BSN (Principal Clinic Coordinator); Elaine Baker, RRT, RPT; Peter Barnard, PhD, RPT; Phil Cagle, MD; James Carter, MD; Sophie Chatzioannou, MD; Karla Conejo-Gonzalez; Kimberly Dubose, RRT; John Haddad, MD; David Hicks, RRT, RPT; Neal Kleiman, MD; Mary Milburn-Barnes, CRT; Chinh Nguyen, RPTF; Michael Reardon, MD; Joseph Reeves-Vets, MD; Steven Sax, MD; Amir Shafir, MD; Ozen Wilson, PhD; Christyne Young PT; Rafael Espada, MD (Principal Investigator 1996-2002); Rose Butanda (1999-2001); Minnie Ellisor (2002); Pamela Fox, MD (1999-2001); Katherine Hale, MD (1998-2000); Everett Hood, RPTF (1998 B 2000); Amy Jahn (1998-2000); Satish PT; Steven Sax, MD; Amir Sharafkhaneh, MD; Owen Wilson, PhD; Christine Young Baker, RRT, RPFT; Peter Barnard, PhD, RPFT; Phil Cagle, MD; James Carter, MD; Sophie Chatzioannou, MD; Karla Conejo-Gonzalez; Kimberly Dubose, RRT; John Haddad, MD; David Hicks, RRT, RPT; Neal Kleiman, MD; Mary Milburn-Barnes, CRT; Chinh Nguyen, RPTF; Michael Reardon, MD; Joseph Reeves-Vets, MD; Steven Sax, MD; Amir Shafir, MD; Ozen Wilson, PhD; Christyne Young PT; Rafael Espada, MD (Principal Investigator 1996-2002); Rose Butanda (1999-2001); Minnie Ellisor (2002); Pamela Fox, MD (1999-2001); Katherine Hale, MD (1998-2000); Everett Hood, RPTF (1998 B 2000); Amy Jahn (1998-2000); Satish PT; Rafael Espada, MD (Principal Investigator); Patrick Ross, MD (Co-Principal Investigator); Tina Bees (Principal Clinic Coordinator); Jan Drake; Charles Emery, PhD; Mark Gerhardt, MD, PhD; Mark King, MD; David Rittinger; Mahasti Rittinger.

Saint Louis University, Saint Louis, MO: Keith Naunheim, MD (Principal Investigator); Robert Gerber, MD (Co-Principal Investigator); Janet Osterloh, RN, MSN (Principal Clinic Coordinator); Susan Borosh; Willard Chamberlain, MD; Sally Frese; Alan Hibbit; Mary Ellen Kleinhenz, MD; Gregg Ruppel; Cary Stoler, MD; Janice Willey, Francisco Alvarez, MD (Co-Principal Investigator, 1999-2000); Robert Keller, MD (Co-Principal Investigator, 1996-2000).

Temple University, Philadelphia, PA: Gerard Criner, MD (Principal Investigator); Satoshi Furukawa, MD (Co-Principal Investigator); Alexander Kopp, MS (Principal Clinic Coordinator); John Apostolakis, MD; Darryl Atwell, MD (Principal Investigator); Mark Iannettoni, MD (Co-Principal Investigator); Catherine Ramirez, BS, RCP (Principal Clinic Coordinator); David Frankville, MD; Paul Friedman, MD; James Harrell, MD; Jeffrey Johnson; David Kapelanski, MD; David Kuperberg, MD; Katherine Larsen, MHA; Trina Limberg, RRT, Michael Magliocco, RN, CPNP, Frank J. Papathoeferias, MD, PhD; Dawn Stassi-D’Ambrosio, RN, Melissa Weeks.

University of Maryland at Baltimore, Baltimore, MD in consortium with Johns Hopkins Hospital, Baltimore, MD: Mark Krupa, MD (Principal Investigator); Arthur Weis, MD; Jennifer Cutler, MD; Robert Frantz, MD; Mclay Gilchrist, MD; Jeffrey Goldstein, MD; John Hopkins, MD; Brian Haas, MD; Harry Hasan, MD; Daniel Kileny, MD; Robert Kopp, MD (Co-Principal Investigator); Lori Zanin, RN, MS.

University of Pennsylvania, Philadelphia, PA: Larry Kiser, MD (Principal Investigator); John Hanssen-Flaschen, MD (Co-Principal Investigator); Mary Louise Dempsey, BSN, RN (Principal Clinic Coordinator), Abass Alavi, MD; Linda Alcorn, Selim Arcosay, MD; Judith Aronchick, MD; Stanley Audi, MD; Bryan Benedict, RRT; Susan Claesens, BS, RRT, CPT, Ron Daniele, MD; Jeffrey Edelman, MD; Warren Geffer, MD; Laura Kotler-Klein, MS; Robert Kotloff, MD; David Lipson, RN, Wallace Miller, Jr., MD; Richard O = Connell, RPTF; Staci Opelman, MSW; Harold Palevsky, MD; William Russell, RPTF; Heather Sheaffer, MSW, Rodger Simcox, RRT; Suzanne Sneider, RRT, CPTF; Jennifer Stone-Wynne, MSW, Gregory Tino, MD; Peter Wahl; James Welter, RRTF; Patricia Ward, David Zisman, MD; James Mendez, MSN, CRNP (1997-2001); Angela Wurster, MSW, CRNP (1997-2001).
MN (Principal Clinician Coordinator), Kimberley Anable, Nancy Battaglia, Louie Boitano, Andrew Bowdile, MD, Leighton Chan, MD, Cindy Chwalik, Bruce Culver, MD, Thurman Gillespy, MD, David Godwin, MD, Jeanne Hoffman, Andrea Ibrahim, MD, Diane Lockhart, Stephen Maglin, MD, Kenneth Martay, MD, Patricia McDowell, Donald Oxorn, MD, Liz Roessler, Michelle Toshima, Susan Golden (1998-2000).

Other participants

Agency for Healthcare Research and Quality, Rockville, MD: Lynn Bosco, MD, MPH, Yen-Pin Chiang, PhD, Carolyn Clancy, MD, Harry Hallesman, DO.

Centers for Medicare and Medicaid Services, Baltimore, MD: Steven M Berkowitz, PhD, Tannis Carino, PhD, Joe Chin, MD, JoAnna Baldwin, Karen McVeary; Anthony Norris, Sarah Shirley; Claudette Sikora Steven Sheingold, PhD (1997-2004).

Coordinating Center, The Johns Hopkins University, Baltimore, MD: Steven Plantaodsi, MD, PhD (Principal Investigator); James Tonascia, PhD (Co-Principal Investigator); Patricia Belt; Amanda Blackford, ScM, Karen Collins; Betty Collison, Ryan Colvin, MPH, John Dodge; Michele Donithan, MHS; Vera Edmonds; Gregory L. Foster, MA; Julie Fuller, Judith Harle; Rosetta Jackson, Shing Lee, ScM, Charlene Levine; Hope Livingston; Jill Meinert; Jennifer Meyers; Deborah Nowakowski; Kapreena Owens; Shangqian Qi, MD; Michael Smith; Brett Simon, MD, Paul Smith, Alice Sternberg, ScM; Mark Van Natta, MHS; Laura Wilson, ScM; Robert Wise, MD.

Cost Effectiveness Subcommitte: Robert M. Kaplan, PhD (Chair); J Sanford Schwartz, MD (Co-Chair); Yen-Pin Chiang, PhD, Marianne C. Fays, PhD, A. Mark Fendrick, MD, Alan J. Moskowitz, MD, Dev Pathak, PhD, Scott Ramsey, MD, PhD, Steven Sheingold, PhD; A. Laurie Shroyer, PhD; Judith Wagner, PhD; Roger Yusen, MD.

Cost Effectiveness Data Center, Fred Hutchinson Cancer Research Center, Seattle, WA: Scott Ramsey, MD, PhD (Principal Investigator), Ruth Etzioni, PhD, Sean Sullivan, PhD, Douglas Wood, MD, Thomas Schroeder, MA, Karma Kreizenbeck, Kristin Berry, MS, Nadia Howlander, MS.

CT Scan Image Storage and Analysis Center, University of Iowa, Iowa City, IA: Eric Hoffman, PhD (Principal Investigator), Janice Cook-Graneroth, BS; Angela Delsing, RT, Junfeng Guo, PhD, Geoffrey McLennan, MD, Brian Mullan, MD, Chris Piker, BS, Joseph Reinhardt, PhD, Blake Wood, Jereen Sieren, RTR, William Stanford, MD.

Data and Safety Monitoring Board: John A. Waldhausler, MD (Chair); Gordon Bernard, MD, David DeVlet, PhD, Mark Ferguson, MD, Eddie Hoover, MD, Robert Levine, MD, Donald Mahler, MD; A. John McSweeny, PhD; Jeanne Wiener-Kronish, PhD; D. Dale Williams, MD; Magdy Younes, MD.

Marketing Center, Temple University, Philadelphia, PA: Gerard Criner, MD (Principal Investigator), Charles Soltot, MBA.

Project Office, National Heart, Lung and Blood Institute, Bethesda, MD Gail Weinmann, MD (Project Officer), Joanne Deshler (Contracting Officer); Dean Follmann, MD, James Kiley, PhD; Margaret Wu, PhD (1996-2001).

Other acknowledgments

Arthur Gelb, MD, Lakewood Regional Medical Center, Lakewood, CA.

Author details

1. Mental Health Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. 2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA. 3. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA. 4. Pulmonary and Critical Care Medicine Section, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. 5. Division of Pulmonary & Critical Care Medicine, University of Washington, Seattle, WA, USA. 6. Department of Surgery, St Louis University, St Louis, MO, USA. 7. Division of Pulmonary & Critical Care Medicine, Temple University, Philadelphia, PA, USA. 8. Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Medical Center and Research Center, University of Colorado, Denver, CO, USA. 9. Division of Pulmonary & Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA. 10. Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 11. Division of Pulmonary & Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Authors' contributions

NDG drafted the manuscript and performed statistical analyses. JLC, JOHN, GC, BM, RAW, APF, FCS, and FLM participated in the design and coordination of the study, interpretation of data and writing the manuscript.

AA and SKM participated in statistical analyses and writing the manuscript, VSF, ML and IL participated in writing the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 19 November 2009 Accepted: 9 March 2010 Published: 9 March 2010

References

1. Priyataro GP, Wright EC, Levin D: Quality of life and its predictors in patients with mild hypoxemia and chronic obstructive pulmonary disease. Arch Intern Med 1984, 144:1613-1619.

2. Monsa E, Fiz JM, Izquierdo J, Alonso J, Coll R, Rosell A, Morera J: Quality of life in severe chronic obstructive pulmonary disease: correlation with lung and muscle function. Respir Med 1998, 92:221-227.

3. McSweeney AJ, Grant I, Heaton RK, Adams KM, Timms RM: Life quality of patients with chronic obstructive pulmonary disease. Arch Intern Med 1982, 142:473-478.

4. Felker B, Katon W, Hedrick SC, Masmussen J, McKnight K, McDonnell MB, Fihn SD: The association between depressive symptoms and health status in patients with chronic pulmonary disease. Gen Hosp Psychiatry 2001, 23:56-61.

5. Culy JA, Graham DP, Stanley MA, Ferguson CJ, Shafikhananeh A, Sousak J, Kunik ME: Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 2006, 47:312-319.

6. Beck JK, Scott SK, Teague RB, Perez FI: Correlates of daily impairment in COPD. Rehabil Psychol 1996, 31:77-84.

7. Kim HF, Kunik ME, Molinari VA, Hillman SL, Lalani S, Oprea CO, Petersen NH, Nahas Z, Goodnight-White S: Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000, 41:465-471.

8. Dahlin J, Janson C: Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest 2002, 122:1633-1637.

9. Borak J, Chodoszcziwa E, Matuszewski A, Zielinski J: Emotional status does not alter exercise tolerance in patients with chronic obstructive pulmonary disease. Eur Respir J 1998, 12:370-373.

10. Engstrom CP, Persson LO, Larsson BO, Ryden A, Sullivan M: Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax 1996, 51:825-830.

11. Witers NJ, Rudkin ST, White RJ: Anxiety and depression in elderly outpatients with chronic obstructive pulmonary disease: prevalence, and validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry 2000, 15:1090-1096.

12. Yohannes AM, Baldwin RC, Connolly MJ: The prevalence of anxiety disorders in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease. J Pain Symptom Manage 1999, 18:69-74.

13. Solano JP, Gomes B, Higginson IJ: A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006, 31:58-69.

14. Karagi B, Rifkin A, Doddi S, Kolli R: The prevalence of anxiety disorders in patients with chronic obstructive pulmonary disease. Am J Psychiatry 1990, 147:200-201.

15. Moore MC, Ziebi BJ: The catastrophic misinterpretation of physiological distress. Behaviour Research and Therapy 1999, 37:1105-1118.

16. Yellowlees PM, Haynes S, Potts N, Ruffin RE: The association between depressive symptom and well being in chronic obstructive pulmonary disease. Eur Respir J 1990, 147:200-201.

17. Withers NJ, Rudkin ST, White RJ: Anxiety and depression in elderly outpatients with chronic obstructive pulmonary disease: prevalence, and validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry 2000, 15:1090-1096.

18. Yohannes AM, Baldwin RC, Connolly MJ: Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: prevalence, and validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry 2000, 15:1090-1096.

19. Kwaal K, Macijauskene J, Engedal K, Laake K: High prevalence of anxiety symptoms in hospitalized geriatric patients. Int J Geriatr Psychiatry 2001, 16:690-693.

20. Finsjo E, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA. 21. Kim HF, Kunik ME, Molinari VA, Hillman SL, Lalani S, Oprea CO, Petersen NH, Nahas Z, Goodnight-White S: Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000, 41:465-471.

22. Moore MC, Ziebi BJ: The catastrophic misinterpretation of physiological distress. Behaviour Research and Therapy 1999, 37:1105-1118.

23. Yellowlees PM, Haynes S, Potts N, Ruffin RE: The association between depressive symptom and well being in chronic obstructive pulmonary disease. Eur Respir J 1990, 147:200-201.

24. Kwaal K, Macijauskene J, Engedal K, Laake K: High prevalence of anxiety symptoms in hospitalized geriatric patients. Int J Geriatr Psychiatry 2001, 16:690-693.

25. Finsjo E, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA. 21. Kim HF, Kunik ME, Molinari VA, Hillman SL, Lalani S, Oprea CO, Petersen NH, Nahas Z, Goodnight-White S: Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000, 41:465-471.

26. Moore MC, Ziebi BJ: The catastrophic misinterpretation of physiological distress. Behaviour Research and Therapy 1999, 37:1105-1118.

27. Yellowlees PM, Haynes S, Potts N, Ruffin RE: The association between depressive symptom and well being in chronic obstructive pulmonary disease. Eur Respir J 1990, 147:200-201.
National Emphysema Treatment Trial Research Group. Chest 1999, 116:1750-1761.

16. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. The efficacy of single and double lung transplantation in severe emphysema. N Engl J Med 2000, 342:2059-2073.

17. Spielberger CD. Manual for the State-Trait Anxiety Inventory (Palo Alto, California: Consulting Psychologists Press 1983).

18. Beck AT, Steer RA. Beck Depression Inventory, Revised Edition (BDI) San Antonio, TX: The Psychological Corporation 1971.

19. Jones PW, Quirk FH, Baveystock CM, Littlejohns PJ. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.

20. Emery CF, Shermer RL, Hauck ER, Hsiao ET, Gen Hosp Psychiatry 1997, 20:77-83.

21. Gen Hosp Psychiatry 1998, 20:128-137.

22. Kellner R, Uhlenhuth EH. The rating and self-rating of anxiety. The British journal of psychiatry 1991, 152.

23. Beck AT, Steer RA. Beck Depression Inventory. 1995 update. Am J Respir Crit Care Med 1995, 152:2198-2199.

24. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981, 123:185-189.

25. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981, 123:659-664.

26. Sculata F, Criner GJ, Lee SM, Mohsenifar Z, Masa JF. Differentiation between dyspnea and its affective components. Respir Res 2003, 4:105-403.

27. Steffen TM, Hacker TA, Nochomovitz M. Respiratory function, cognitions, and panic in chronic obstructive pulmonary patients. Behav Res Ther 1992, 30:75-77.

28. Giardino ND, Borson S, Van Korff M, Chan L. Beliefs about breathlessness are associated with disability in COPD. American Thoracic Society annual meeting, May 2004; Orlando, FL.

29. Shekhar A, Sajbyk TJ, Gehlen DR, Rainine DG. The amygualda, panic disorder, and cardiovascular responses. Ann N Y Acad Sci 2003, 985:308-325.

30. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006, 119:21-31.

31. Meehan-Johannesen AI, Sheehan CD, Roy-Byrne PP, Cusack MG, Stein MB. Using five questions to screen for five common mental disorders in primary care: diagnostic accuracy of the Anxiety and Depression Detector. Gen Hosp Psychiatry 2006, 28:108-118.

32. Borson S, McDonald GJ, Gayle T, Defebbrach M, LakhsmiNarayan S, VanTuinen C. Improvement in mood, physical symptoms, and function with nortrypine for patients with chronic obstructive pulmonary disease. Psychosomatics 1992, 33:190-201.

33. Argyropoulopou P, Patakis D, Koukou A, Vasilidis P, Georgopoulus D. Buspiron effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiracion 1993, 60:216-220.

34. Papp LA, Weiss JR, Greenberg JE, Riikin A, Scharf SM, Gorman JM, Klen DF. Seltrazine for chronic obstructive pulmonary disease and comorbidity anxiety and mood disorders. Am J Psychiatry 1995, 152:1531.

35. Smoller JW, Pollack MH, Systrom D, Kradin RL. Gender and COPD in patients attending a pulmonary clinic, Chest 2005, 128:2012-2016.

36. Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, Allegra L, Centanni S. Anxiety and depression in COPD patients: The roles of gender and disease severity. Respir Med 2006, 100:1767-1774.

37. Stahl E, Lindberg A, Jansson SA, Ronmark E, Svensson K, Anderson F, Lofdahl CG, Lundback B. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005, 3:56.

38. Neuman A, Gunnbomadott M, Tunsater A, Nystrom L, Franklin KA, Norman E, Janson C. Dyspnea in relation to symptoms of anxiety and depression: A prospective population study. Respir Med 2006, 100:1843-1849.

39. Porcelli MS, Turchinov M, Nechamovit M. Reference spirometric values, cognitions, and panic in chronic obstructive pulmonary patients. Behav Res Ther 1992, 30:75-77.

40. Giardino ND, Borson S, Von Korff M, Chan L. Beliefs about breathlessness are associated with disability in COPD. American Thoracic Society annual meeting, May 2004; Orlando, FL.

41. Shekhar A, Sajbyk TJ, Gehlen DR, Rainine DG. The amygualda, panic disorder, and cardiovascular responses. Ann N Y Acad Sci 2003, 985:308-325.

42. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006, 119:21-31.

43. Meehan-Johannesen AI, Sheehan CD, Roy-Byrne PP, Cusack MG, Stein MB. Using five questions to screen for five common mental disorders in primary care: diagnostic accuracy of the Anxiety and Depression Detector. Gen Hosp Psychiatry 2006, 28:108-118.

44. Borson S, McDonald GJ, Gayle T, Defebbrach M, LakhsmiNarayan S, VanTuinen C. Improvement in mood, physical symptoms, and function with nortrypine for patients with chronic obstructive pulmonary disease. Psychosomatics 1992, 33:190-201.

45. Argyropoulopou P, Patakis D, Koukou A, Vasilidis P, Georgopoulus D. Buspiron effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiracion 1993, 60:216-220.

46. Papp LA, Weiss JR, Greenberg JE, Riikin A, Scharf SM, Gorman JM, Klen DF. Seltrazine for chronic obstructive pulmonary disease and comorbidity anxiety and mood disorders. Am J Psychiatry 1995, 152:1531.

47. Smoller JW, Pollack MH, Systrom D, Kradin RL. Seltrazine effects on dyspnea in patients with obstructive airways disease. Psychosomatics 1998, 39:24-29.

48. Kunik ME, Braun U, Stanley MA, Wristers K, Molinari V, Stoebehr D, Orengo CA. A session cognitive behaviour therapy for elderly patients with chronic obstructive pulmonary disease. Psychol Med 2001, 31:717-723.

49. de Godoy DV, de Godoy RF. A randomized controlled trial of the effect of psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2003, 84:1154-1157.

50. Emery CF. Effects of age on physiological and psychological functioning among COPD patients in an exercise program. J Aging Health 1994, 6:3-16.

51. Emery CF, Schein RL, Hauck ER, MacIntyre NR. Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. Health Psychol 1997, 17:232-240.

52. Emery CF, Shermor RL, Hauck ER, Hsiao ET, MacIntyre NR. Cognitive and psychological outcomes of exercise in a 1-year follow-up study of patients with chronic obstructive pulmonary disease. Health Psychol 2003, 22:598-604.

53. Guell R, Resqueta V, Sangenis M, Morante F, Martorell B, Casan P, Guyatt GH. Impact of pulmonary rehabilitation on psychosocial morbidity in patients with severe COPD. Chest 2006, 129:899-904.
66. Kayahan B, Karapolat H, Atynoprlk E, Atasever A, Ozturk O: Psychological outcomes of an outpatient pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med 2006, 100:1050-1057.

67. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.

doi:10.1186/1465-9921-11-29

Cite this article as: Giardino et al.: Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study. Respiratory Research 2010 11:29.